M. Isaac

发表

Cost-Benefit & Cost-Effectiveness Analysis of the Rapid Onset of Selective Serotonin Reuptake Inhibitors by Augmentation

M. Tome, M. Isaac, 1997, International journal of psychiatry in medicine.

Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.

M. Isaac, M. Isaac, 2004, Diabetes care.

Psychosexual and Psychosocial Aspects of Spinal Cord Disease

M. Isaac, 1997 .

Review: Problems associated with long-term treatment with selective serotonin reuptake inhibitors

M. Briley, M. Isaac, C. Moret, 2009, Journal of psychopharmacology.

Mirtazapine in menopausal depression

M. Tome, M. Isaac, 1998, European Neuropsychopharmacology.

Effect of Treating Depression on Quality-of-Life and Exercise Tolerance in Severe COPD

N. Eiser, M. Isaac, S. Karvounis, 2005, COPD.

Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects

M. Isaac, M. Isaac, 2003, Human psychopharmacology.

Anatomy as a Key to Function of the Spinal Cord

M. Isaac, 1992 .

Individual dietary education reduces olanzapine associated weight gain

M. Isaac, 2006, Evidence-based mental health.

Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol.

C. Robert Cloninger, J. Watson, M. Tome, 1997, Journal of affective disorders.

Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency

M. Tome, C. Holland, M. Isaac, 1997, International clinical psychopharmacology.

Spinal Modulation of Noxious Stimuli

E. Critchley, M. Isaac, 1997 .

Where are we going with SSRIs?

M. Isaac, 1999, European Neuropsychopharmacology.

Treating Depression with SNRIs: Who Will Benefit Most?

M. Isaac, 2008, CNS Spectrums.